Table 2.
Cumulative Fracture Incidence and Correlations With Hip BMD T‐Score at 24 Months
| Cohort 1: BPnaïve patients (n = 11,973) a | Cohort 2: BP‐treated patients (n = 3422) | |||||
|---|---|---|---|---|---|---|
| Fracture type | Cumulative fracture incidence | Correlation between cumulative fracture incidence and hip BMD T‐score | Hazard ratio (95% CI) for hip T‐score | Cumulative fracture incidence | Correlation between cumulative fracture incidence and hip BMD T‐score | Hazard ratio (95% CI) for hip T‐score |
| % (95% CI) | (Pearson's correlation coefficient) | % (95% CI) | (Pearson's correlation coefficient) | |||
| Any | 6.29 (5.86–6.73) | −0.92 | 0.63 (0.59–0.67) | 8.39 (7.49–9.35) | −0.94 | 0.69 (0.62–0.77) |
| Nonvertebral | 5.41 (5.02–5.83) | −0.93 | 0.65 (0.61–0.70) | 7.31 (6.47–8.21) | −0.94 | 0.69 (0.61–0.77) |
| Vertebral | 1.02 (0.85–1.21) | −0.79 | 0.50 (0.43–0.58) | 1.34 (1.00–1.77) | −0.92 | 0.68 (0.53–0.88) |
| Hip | 1.20 (1.02–1.41) | −0.72 | 0.45 (0.39–0.52) | 1.40 (1.05–1.84) | −0.61 | 0.45 (0.37–0.55) |
| Nonhip nonvertebral | 4.32 (3.96–4.69) | −0.96 | 0.73 (0.68–0.78) | 6.02 (5.26–6.85) | −0.98 | 0.79 (0.70–0.90) |
| Major osteoporotic | 4.53 (4.16–4.91) | −0.89 | 0.58 (0.54–0.62) | 6.08 (5.31–6.91) | −0.94 | 0.70 (0.62–0.79) |
BMD = bone mineral density; BP = bisphosphonate; CI = confidence interval.
a
Patients had not received BP treatment for at least 12 months prior to index date.